StockData
Aurinia Pharmaceuticals Inc. logo

Aurinia Pharmaceuticals Inc. (AUPH) stock

AUPHNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 13/3059% below fair value
$15.40−0.08 (-0.52%)

Close on Nov 17, 2026Market cap $2.06BP/E 6.7Yield –

Aurinia Pharmaceuticals price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Aurinia Pharmaceuticals's price to sales ratio was 6.9× on Nov 11, 2026, against 8.0× a year earlier. Over the last 5 years it ranged from 4.1× to 41.0×, with a median of 6.9×.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 20266.9×−1.0
2025Dec 31, 20257.9×+2.1
2024Dec 31, 20245.8×−2.3
2023Dec 29, 20238.1×+3.4
2022Dec 30, 20224.8×−36.3
2021Dec 31, 202141.0×–

More Aurinia Pharmaceuticals figures

See a number that looks wrong?